更新于：2024-11-01

High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排

更新于：2024-11-01

基本信息

别名

HGBL with MYC and BCL2 and/or BCL6 Rearrangements、High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements、High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

+ [9]

简介

High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.

关联

项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的药物

Glofitamab

格菲妥单抗

靶点

CD20 x CD3

作用机制

CD20抑制剂 [+2]

在研机构

Roche Holding AG [+9]

原研机构

F. Hoffmann-La Roche Ltd.

在研适应症

复发性弥漫性大B细胞淋巴瘤 [+22]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2023-03-24

Loncastuximab tesirine

泰朗妥昔单抗

靶点

CD19 x DNA

作用机制

CD19抑制剂 [+3]

在研机构

ADC Therapeutics SA [+4]

原研机构

ADC Therapeutics SA

在研适应症

复发性弥漫性大B细胞淋巴瘤 [+16]

非在研适应症

伯基特淋巴瘤 [+7]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2021-04-23

Polatuzumab Vedotin-Piiq

维泊妥珠单抗

靶点

CD79B x Tubulin

作用机制

CD79B抑制剂 [+1]

在研机构

Roche Registration GmbH [+10]

原研机构

GeneTech, Inc.

在研适应症

难治性淋巴瘤 [+21]

非在研适应症

难治性滤泡性淋巴瘤

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2019-06-10

项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的临床试验

NCT06649812 / Not yet recruiting临床2期IIT

A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

开始日期2025-01-17

申办/合作机构

National Cancer Institute

NCT06588205 / Not yet recruitingN/AIIT

Multicenter, Observational, Retrospective-prospective Study Exploring the Clinical Impact of MYC Aberrations and Their Relationship with Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

开始日期2024-12-01

申办/合作机构-

NCT06544265 / Recruiting临床1期

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced with CD19 KIR-CAR, in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

开始日期2024-10-01

申办/合作机构

Verismo Therapeutics, Inc.初创企业

100 项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的临床结果

登录后查看更多信息

100 项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的转化医学

登录后查看更多信息

0 项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的专利（医药）

登录后查看更多信息

项与高级别B细胞淋巴瘤伴 MYC 和 BCL2 和/或 BCL6 重排相关的文献（医药）

2018-09-01·Modern Pathology1区 · 医学

MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas

1区 · 医学

Article

作者: Huang, Wenting ; Li, Shaoying ; Yin, C Cameron ; Lin, Pei ; Xu, Jie ; Khoury, Joseph ; Tang, Guilin ; Oki, Yasuhiro ; Konoplev, Sergej ; Medeiros, L Jeffrey ; Wang, Wei

High-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements (triple hit lymphoma) are uncommon. We studied the clinicopathologic features of 40 patients with triple hit lymphoma and compared them to 157 patients with MYC/BCL2 double hit lymphoma and 13 patients with MYC/BCL6 double hit lymphoma. The triple hit lymphoma group included 25 men and 15 women with a median age of 61 years (range, 34-85). Nine patients had a history of B-cell lymphoma. Histologically, 23 (58%) cases were diffuse large B-cell lymphoma and 17 cases had features of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Most cases of triple hit lymphoma were positive for CD10 (100%), BCL2 (95%), BCL6 (82%), MYC (74%), and 71% with MYC and BCL2 coexpression. P53 was overexpressed in 29% of triple hit lymphoma cases. The clinicopathological features of triple hit lymphoma patients were similar to patients with MYC/BCL2 and MYC/BCL6 double hit lymphoma, except that triple hit lymphoma cases were more often CD10 positive compared with MYC/BCL6 double hit lymphoma (p < 0.05). Induction chemotherapy used was similar for patients with triple hit lymphoma and double hit lymphoma and overall survival in triple hit lymphoma patients was 17.6 months, similar to the overall survival of patients with double hit lymphoma (p = 0.67). Patients with triple hit lymphoma showing P53 overexpression had significantly worse overall survival compared with those without P53 overexpression (p = 0.04). On the other hand, double expressor status and prior history of B-cell lymphoma did not correlate with overall survival. In conclusion, most patients with triple hit lymphoma have an aggressive clinical course and poor prognosis and these tumors have a germinal center B-cell immunophenotype, similar to patients with double hit lymphomas. P53 expression is a poor prognostic factor in patients with triple hit lymphoma.